Pemvidutide (ALT-801) is a dual GLP-1/glucagon receptor agonist developed by Altimmune. It is being studied for obesity and MASH (metabolic dysfunction-associated steatohepatitis), with promising early results for both weight loss and liver fat reduction.

In the MOMENTUM Phase 2 trial, Pemvidutide showed approximately 15.6% weight loss at 48 weeks at the highest dose, along with significant reductions in liver fat. The dual-agonist approach targets both metabolic and hepatic outcomes.

Pemvidutide is administered as a weekly subcutaneous injection. Phase 2 studies tested doses of 1.2 mg, 1.8 mg, and 2.4 mg weekly. The calculator helps determine injection volumes based on vial concentration.